Moreover, it is reported that constitutive NF-κB activation is common in childhood ALL without any difference between T- and B-ALLs [22], implicating that β-catenin might not inhibit NF-κB activity in ALL, which is inconsistent with previous reports in colon, breast, and liver cancer [12, 23, 27]. The gene discussed is NFKB1; the disease is liver cancer.